Efficacy and Safety Results From a Pivotal, Phase 3 Study of TrenibotulinumtoxinE for Treatment of Moderate-to-Severe Glabellar Lines in Toxin-Experienced and Toxin-Naive Adults

Clicks: 11
ID: 333999
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #122 of 129 articles by views in Aesthetic surgery journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 129 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Glabellar lines (GLs) are commonly treated with botulinum toxins; however, individuals may be hesitant to undergo treatment because of uncertainty around outcomes. OBJECTIVES: This Phase 3, double-blind, placebo-controlled study evaluated the safety and efficacy of trenibotulinumtoxinE (trenibotE), a botulinum neurotoxin serotype E, in toxin-naive and toxin-experienced adults with moderate-to-severe GL. METHODS: Participants were randomized 3:1 to receive either trenibotE (700 U) or placebo. The rigorous, multicomponent, primary endpoint was achieving a Grade 0 or 1 (None or Mild), with ≥2-grade improvement on the Facial Wrinkle Scale (FWS) at maximum frown by investigator and participant assessments on Day 7. Additional endpoints included FWS improvement over time, patient-reported outcomes, and assessments in participants who had appearance-related psychological impacts. Safety was monitored throughout. RESULTS: At Day 7, trenibotE was associated with significantly higher responder rates (60.0%) compared with placebo (0.6%) (P < .0001). Improvements began at Hour 8 (P < .001, unadjusted), peaked at Day 7, and returned to moderate-to-severe GL severity by Day 21. Treatment satisfaction was higher following trenibotE at Hour 8 (33.0% vs 13.8%; P < .0001, unadjusted), Hour 24 (59.2% vs 17.3%; P < .0001), and Day 7 (77.6% vs 5.1%). Higher satisfaction with natural-looking results following trenibotE treatment was first observed at Hour 8 (P < .0001, unadjusted) and peaked at Day 7 (78.5% vs 9.0% placebo; P < .0001). Most adverse events were mild, nonserious, and unrelated to study treatment. CONCLUSIONS: TrenibotE significantly improved GL severity with rapid results and short duration of effect. Participants reported high satisfaction with treatment and natural-looking results. The overall benefit-risk profile was favorable. LEVEL OF EVIDENCE: 1 (RISK): For image description, please refer to the figure legend and surrounding text.
Reference Key
openalex_W7223560673 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Cheryl Burgess, Marion Moers-Carpi, Magdalena Boczarska‐Jedynak, Brian S. Biesman, Charles Boyd, Daniela Greiner-Krüger, Deirdre Hooper, Keith A Marcus, Chung-Yi Chiang, Grace S. Park, Sandhya V. Shimoga, Amy S. Weitzenfeld, Joan-En Chang-Lin
Are you one of these authors? Claim your profile
Journal Aesthetic surgery journal
Year 2026
DOI
10.1093/asj/sjag198
URL
https://academic.oup.com/asj/advance-article-pdf/doi/10.1093/asj/sjag198/72486832/sjag198.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.